Figure 5

Australasian versus US comparison in thromboembolic treatment decisions. a: Australasian versus US Comparison in Thromboembolic Treatment Decisions for Scenarios of Paroxysmal AF < 48 hours with Low CHADS2 Score. US cardiologists more often chose no thromboembolic treatment, fewer used aspirin, and more selected heparin or other strategies compared to their Australasian counterparts. The category “Other” included Australasian survey responses of clopidogrel, US responses of dabigatran and rivaroxaban, as well as, write-in responses in both surveys. Abbreviations: AF, atrial fibrillation; EP, emergency medicine physicians; US, United States. b: Australasian versus US Comparison in Thromboembolic Treatment Decisions for Scenarios of New Onset AF ≥ 48 hours with Low CHADS2 Score. There were significant differences among both physician groups. US cardiologists chose no thromboembolic treatment and heparin more often, and used aspirin and warfarin alone less often than their Australasian colleagues. US EPs more often selected not to use thromboembolic treatment compared to their Australasian counterparts, and selected aspirin and heparin less frequently. Abbreviations: AF, atrial fibrillation; EP, emergency medicine physicians; US, United States.